Daratumumab in transfusion‐dependent patients with low or intermediate‐1 risk myelodysplastic syndromes

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	American journal of hematology 2021-04, Vol.96 (4), p.E111-E114
Hauptverfasser:	Garcia‐Manero, Guillermo, Diez‐Campelo, Maria, Vellenga, Edo, Jacoby, Meagan A., Merchan, Brayan, Breems, Dimitri, Cortelezzi, Agostino, Doronin, Vadim, Gomez, Valle, Beckers, Marielle, Della Porta, Matteo Giovanni, Varsos, Helen, Xiu, Liang, DeAngelis, Nikki, Nnane, Ivo, Rose, Esther, Eygen, Koen
Format:	Artikel
Sprache:	eng
Schlagworte:	ADP-ribosyl Cyclase 1 - antagonists & inhibitors Aged Aged, 80 and over Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacokinetics Antibodies, Monoclonal - therapeutic use Erythrocyte Transfusion Female Fever - chemically induced Follow-Up Studies Hematology Humans Immunologic Factors - adverse effects Immunologic Factors - therapeutic use Immunotherapy Male Membrane Glycoproteins - antagonists & inhibitors Middle Aged Monoclonal antibodies Myelodysplastic syndrome Myelodysplastic syndromes Myelodysplastic Syndromes - drug therapy Myelodysplastic Syndromes - epidemiology Myelodysplastic Syndromes - therapy Neutropenia - chemically induced Pneumonia - chemically induced Proof of Concept Study Risk Thrombocytopenia - chemically induced
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!